Molecular farming - The slope of enlightenment

被引:100
作者
Fischer, Rainer [1 ,2 ,3 ]
Buyel, Johannes F. [2 ,4 ]
机构
[1] IBRI, 1345 W 16th St,Suite 300, Indianapolis, IN 45202 USA
[2] Rhein Westfal TH Aachen, Inst Mol Biotechnol, Worringerweg 1, D-52074 Aachen, Germany
[3] Purdue Univ, Purdue Inst Inflammat Immunol & Infect Dis, 207 S Martin Jischke Dr, W Lafayette, IN 47907 USA
[4] Fraunhofer Inst Mol Biol & Appl Ecol IME, Forckenbeckstr 6, D-52074 Aachen, Germany
关键词
Molecular farming; Plant platforms; Industrial and pharmaceutical products; Development cycle; Regulatory; LARGE-SCALE PRODUCTION; RECOMBINANT PHARMACEUTICAL PROTEINS; MONOCLONAL-ANTIBODY; COMMERCIAL PRODUCTION; HIGH-LEVEL; TOBACCO; PLANTS; EXPRESSION; CELL; VACCINES;
D O I
10.1016/j.biotechadv.2020.107519
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Molecular farming can be defined as the use of plants to produce recombinant protein products. The technology is now > 30 years old. The early promise of molecular farming was based on three perceived advantages: the low costs of growing plants, the immense scalability of agricultural production, and the inherent safety of plants as hosts for the production of pharmaceuticals. This resulted in a glut of research publications in which diverse proteins were expressed in equally diverse plant-based systems, and numerous companies were founded hoping to commercialize the new technology. There was a moderate degree of success for companies producing nonpharmaceutical proteins, but in the pharmaceutical sector the anticipation raised by promising early research was soon met by the cold hard reality of industrial pragmatism. Plants did not have a track record of success in pharmaceutical protein manufacturing, lacked a regulatory framework, and did not perform as well as established industry platforms. Negative attitudes towards genetically modified plants added to the mix. By the early 2000s, major industry players started to lose interest and pharmaceutical molecular farming fell from a peak of expectation into a trough of disillusionment, just as predicted by the Gartner hype cycle. But many of the pioneers of molecular farming have refocused their activities and have worked to address the limitations that hampered the first generation of technologies. The field has now consolidated around a smaller number of better-characterized platforms and has started to develop standardized methods and best practices, mirroring the evolution of more mature industry sectors. Likewise, attention has turned from proof-of-principle studies to realistic techno-economic modeling to capture significant niche markets, replicating the success of the industrial molecular farming sector. Here we argue that these recent developments signify that pharmaceutical molecular farming is now climbing the slope of enlightenment and will soon emerge as a mature technology.
引用
收藏
页数:16
相关论文
共 112 条
  • [1] A Plant-Derived Recombinant Human Glucocerebrosidase Enzyme-A Preclinical and Phase I Investigation
    Aviezer, David
    Brill-Almon, Einat
    Shaaltiel, Yoseph
    Hashmueli, Sharon
    Bartfeld, Daniel
    Mizrachi, Sarah
    Liberman, Yael
    Freeman, Arnold
    Zimran, Ari
    Galun, Eithan
    [J]. PLOS ONE, 2009, 4 (03):
  • [2] Novel enzyme replacement therapy for Gaucher disease: Ongoing Phase III clinical trial with recombinant human glucocerebrosidase expressed in plant cells
    Aviezer, David
    Almon-Brill, Einat
    Shaaltiel, Yoseph
    Galili, Gad
    Chertkoff, Raul
    Hashmueli, Sharon
    Galun, Eithan
    Zimran, Ari
    [J]. MOLECULAR GENETICS AND METABOLISM, 2009, 96 (02) : S13 - S14
  • [3] Rapid, high-yield production in plants of individualized idiotype vaccines for non-Hodgkin's lymphoma
    Bendandi, M.
    Marillonnet, S.
    Kandzia, R.
    Thieme, F.
    Nickstadt, A.
    Herz, S.
    Froede, R.
    Inoges, S.
    Lopez-Diaz de Cerio, A.
    Soria, E.
    Villanueva, H.
    Vancanneyt, G.
    McCormick, A.
    Tuse, D.
    Lenz, J.
    Butler-Ransohoff, J. -E.
    Klimyuk, V.
    Gleba, Y.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 (12) : 2420 - 2427
  • [4] Design of a Type-1 Diabetes Vaccine Candidate Using Edible Plants Expressing a Major Autoantigen
    Bertini, Edoardo
    Merlin, Matilde
    Gecchele, Elisa
    Puggia, Andrea
    Brozzetti, Annalisa
    Commisso, Mauro
    Falorni, Alberto
    Bini, Vittorio
    Klymyuk, Victor
    Pezzotti, Mario
    Avesani, Linda
    [J]. FRONTIERS IN PLANT SCIENCE, 2018, 9
  • [5] Engineering Plastid Genomes: Methods, Tools, and Applications in Basic Research and Biotechnology
    Bock, Ralph
    [J]. ANNUAL REVIEW OF PLANT BIOLOGY, VOL 66, 2015, 66 : 211 - 241
  • [6] Analysis of a Multi-component Multi-stage Malaria Vaccine Candidate-Tackling the Cocktail Challenge
    Boes, Alexander
    Spiegel, Holger
    Voepel, Nadja
    Edgue, Gueven
    Beiss, Veronique
    Kapelski, Stephanie
    Fendel, Rolf
    Scheuermayer, Matthias
    Pradel, Gabriele
    Bolscher, Judith M.
    Behet, Marije C.
    Dechering, Koen J.
    Hermsen, Cornelus C.
    Sauerwein, Robert W.
    Schillberg, Stefan
    Reimann, Andreas
    Fischer, Rainer
    [J]. PLOS ONE, 2015, 10 (07):
  • [7] Production of recombinant proteins in plant root exudates
    Borisjuk, NV
    Borisjuk, LG
    Logendra, S
    Petersen, F
    Gleba, Y
    Raskin, I
    [J]. NATURE BIOTECHNOLOGY, 1999, 17 (05) : 466 - 469
  • [8] BACTERIAL DRY-MATTER CONTENT AND BIOMASS ESTIMATIONS
    BRATBAK, G
    DUNDAS, I
    [J]. APPLIED AND ENVIRONMENTAL MICROBIOLOGY, 1984, 48 (04) : 755 - 757
  • [9] Tobacco BY-2 cell-free lysate: an alternative and highly-productive plant-based in vitro translation system
    Buntru, Matthias
    Vogel, Simon
    Spiegel, Holger
    Schillberg, Stefan
    [J]. BMC BIOTECHNOLOGY, 2014, 14
  • [10] Very-large-scale production of antibodies in plants: The biologization of manufacturing
    Buyel, J. F.
    Twyman, R. M.
    Fischer, R.
    [J]. BIOTECHNOLOGY ADVANCES, 2017, 35 (04) : 458 - 465